RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 certainty unassessable-55%
versus placebo
nivolumab plus ipilimumab vs. placebo 1 certainty unassessablestatistically conclusive-71%

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive